Serological Responses to a Norovirus Nonstructural Fusion Protein after Vaccination and Infection.
作者信息
Hesse Shayla, Neill Frederick H, Estes Mary K, Shanker Sreejesh, Prasad B V Venkataram, Ferreira Jennifer, Atmar Robert L
机构信息
Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA.
出版信息
Clin Vaccine Immunol. 2015 Dec 9;23(2):181-3. doi: 10.1128/CVI.00595-15. Print 2016 Feb.
Abstract
The performance of an assay to detect antibodies to a norovirus nonstructural fusion protein, designated VPR and consisting of three proteins (GI.1 virus protein genome-linked [VPg], a virus protease, and an RNA-dependent RNA polymerase), was evaluated. The assay sensitivity and specificity were 74.5% and >95%, respectively, for identifying GI.1 norovirus infection among persons who received either a monovalent GI.1 norovirus virus-like particle (VLP) vaccine or placebo by the intranasal route followed by an oral live GI.1 norovirus challenge.
摘要
相似文献
1
Serological Responses to a Norovirus Nonstructural Fusion Protein after Vaccination and Infection.
Clin Vaccine Immunol. 2015 Dec 9;23(2):181-3. doi: 10.1128/CVI.00595-15. Print 2016 Feb.
2
Serological Correlates of Protection against a GII.4 Norovirus.
Clin Vaccine Immunol. 2015 Aug;22(8):923-9. doi: 10.1128/CVI.00196-15. Epub 2015 Jun 3.
3
Genotype considerations for virus-like particle-based bivalent norovirus vaccine composition.
Clin Vaccine Immunol. 2015 Jun;22(6):656-63. doi: 10.1128/CVI.00015-15. Epub 2015 Apr 22.
4
Functionality and avidity of norovirus-specific antibodies and T cells induced by GII.4 virus-like particles alone or co-administered with different genotypes.
Vaccine. 2018 Jan 25;36(4):484-490. doi: 10.1016/j.vaccine.2017.12.009. Epub 2017 Dec 13.
5
A novel intramuscular bivalent norovirus virus-like particle vaccine candidate--reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults.
J Infect Dis. 2014 Dec 1;210(11):1763-71. doi: 10.1093/infdis/jiu337. Epub 2014 Jun 20.
6
Robust mucosal-homing antibody-secreting B cell responses induced by intramuscular administration of adjuvanted bivalent human norovirus-like particle vaccine.
Vaccine. 2015 Jan 15;33(4):568-76. doi: 10.1016/j.vaccine.2014.09.073. Epub 2014 Nov 22.
7
In Depth Breadth Analyses of Human Blockade Responses to Norovirus and Response to Vaccination.
Viruses. 2019 Apr 26;11(5):392. doi: 10.3390/v11050392.
8
Simultaneous Immunization with Multivalent Norovirus VLPs Induces Better Protective Immune Responses to Norovirus Than Sequential Immunization.
Viruses. 2019 Nov 2;11(11):1018. doi: 10.3390/v11111018.
9
Mucosal Antibodies Induced by Intranasal but Not Intramuscular Immunization Block Norovirus GII.4 Virus-Like Particle Receptor Binding.
Viral Immunol. 2016 Jun;29(5):315-9. doi: 10.1089/vim.2015.0141. Epub 2016 May 2.
10
Persistence of Antibodies to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: 1-Year Follow-up With Memory Probe Vaccination.
J Infect Dis. 2019 Jul 19;220(4):603-614. doi: 10.1093/infdis/jiz170.
引用本文的文献
1
Mapping human norovirus antigens during infection reveals the breadth of the humoral immune response.
NPJ Vaccines. 2023 Jun 6;8(1):87. doi: 10.1038/s41541-023-00683-1.
2
Profiling of humoral immune responses to norovirus in children across Europe.
Sci Rep. 2022 Aug 22;12(1):14275. doi: 10.1038/s41598-022-18383-6.
3
Serological Humoral Immunity Following Natural Infection of Children with High Burden Gastrointestinal Viruses.
Viruses. 2021 Oct 9;13(10):2033. doi: 10.3390/v13102033.
4
Pairing of Parental Noroviruses with Unequal Competitiveness Provides a Clear Advantage for Emergence of Progeny Recombinants.
Appl Environ Microbiol. 2021 Jan 15;87(3). doi: 10.1128/AEM.02015-20.
5
Emergence of norovirus strains: A tale of two genes.
Virus Evol. 2019 Nov 25;5(2):vez048. doi: 10.1093/ve/vez048. eCollection 2019 Jul.
6
Mapping and modeling of a strain-specific epitope in the Norwalk virus capsid inner shell.
Virology. 2016 May;492:232-41. doi: 10.1016/j.virol.2016.02.019. Epub 2016 Mar 21.
本文引用的文献
1
Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults.
J Infect Dis. 2015 Mar 15;211(6):870-8. doi: 10.1093/infdis/jiu497. Epub 2014 Sep 9.
2
Determination of the 50% human infectious dose for Norwalk virus.
J Infect Dis. 2014 Apr 1;209(7):1016-22. doi: 10.1093/infdis/jit620. Epub 2013 Nov 18.
3
Epidemiology of human noroviruses and updates on vaccine development.
Curr Opin Gastroenterol. 2014 Jan;30(1):25-33. doi: 10.1097/MOG.0000000000000022.
4
Norovirus disease in the United States.
Emerg Infect Dis. 2013 Aug;19(8):1198-205. doi: 10.3201/eid1908.130465.
5
Norovirus virus-like particle vaccines for the prevention of acute gastroenteritis.
Expert Rev Vaccines. 2013 Feb;12(2):155-67. doi: 10.1586/erv.12.145.
6
Antibody responses to norovirus genogroup GI.1 and GII.4 proteases in volunteers administered Norwalk virus.
Clin Vaccine Immunol. 2012 Dec;19(12):1980-3. doi: 10.1128/CVI.00411-12. Epub 2012 Oct 3.
7
Norovirus vaccine against experimental human Norwalk Virus illness.
N Engl J Med. 2011 Dec 8;365(23):2178-87. doi: 10.1056/NEJMoa1101245.
8
Norovirus gastroenteritis.
N Engl J Med. 2009 Oct 29;361(18):1776-85. doi: 10.1056/NEJMra0804575.
Zotero 插件